NEW YORK (GenomeWeb News) – PerkinElmer last week filed a suit against UK-based Intema seeking to invalidate that firm's US patent covering a Down syndrome test.

The suit, which was filed in the US District Court for the District of Massachusetts, seeks a declaration from the court that one or more of the claims of US Patent No. 6,573,103 are invalid. The patent is entitled, "Antenatal Screening for Down's Syndrome," and was issued in June 2003.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.